Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Oct 3 - Oct 8
Tirzepatide dose-dependently leads to clinically significant reductions in glycemic parameters and body weight and has been shown to have stronger effects in reducing these parameters than standard antidiabetic therapy
Compounded medications have not undergone the same rigorous testing as FDA-approved treatments, leading to potential risks such as incorrect dosing, unsafe ingredients, and counterfeit products
Food & Drug Administration, FDA approves first oral GLP-1 treatment for type 2 diabetes (2019)
X.et al (1998)
US$ 29.13
US$ 25.74
US$ 21.85
US$ 25.12
